SCHEMBL5860044

SCHEMBL5860044

CCOC(=O)c1c(Cl)nc2ccccc2c1CCl

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.62
SMN1; SMN2 Q16637 3/20 0.62
ALDH1A1 P00352 3/20 0.62
MAPT P10636 2/20 0.59
LMNA P02545 2/20 0.53
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
GAA P10253 2/20 0.47
HPGD P15428 2/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
GLA P06280 1/20 0.46
POLB P06746 1/20 0.46
NMT2 O60551 1/20 0.46
NMT1 P30419 1/20 0.46
ADORA3 P0DMS8 1/20 0.45
TSHR P16473 1/20 0.45
CASP1 P29466 1/20 0.45
CASP7 P55210 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7248226 0.85 KDM4E (0.70) KDM4ESMN1; SMN2ALDH1A1MAPTLMNA
SCHEMBL1063212 0.85 KDM4E (0.59) KDM4ESMN1; SMN2ALDH1A1MAPTLMNA
SCHEMBL29799068 0.85 KDM4E (0.59) KDM4ESMN1; SMN2ALDH1A1MAPTLMNA
SCHEMBL27327783 0.84 KDM4E (0.57) KDM4ESMN1; SMN2ALDH1A1MAPTLMNA
SCHEMBL5859919 0.83 TSHR (0.48) KDM4ESMN1; SMN2ALDH1A1MAPTMEN1
SCHEMBL5860075 0.82 ALDH1A1 (0.49) KDM4ESMN1; SMN2ALDH1A1MAPTLMNA
SCHEMBL6222290 0.82 KDM4E (0.45) KDM4ESMN1; SMN2ALDH1A1LMNAMEN1
SCHEMBL14463535 0.82 SMN1; SMN2 (0.74) KDM4ESMN1; SMN2ALDH1A1MAPTLMNA
SCHEMBL5859933 0.81 KDM4E (0.43) KDM4ESMN1; SMN2ALDH1A1MAPTLMNA
SCHEMBL5860955 0.80 ALDH1A1 (0.42) KDM4ESMN1; SMN2ALDH1A1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7135478-B2 Analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them SOCIETE DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2006-11-14 US disclosed
US-7053102-B2 Analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them SOCIETE DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2006-05-30 US disclosed
US-20050038064-A1 Anticarcinogenic agents; breast, colon, lung, prostate, ovarian, and gastric cancers, leukemia, melanomas; (5R)-5-ethyl-9,10-difluoro-5-hydroxy-4,5,13,15-tetrahydro-1H,3H-oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione SOCIETE DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) 2005-02-17 US disclosed
US-20040254163-A1 New analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them SOCIETE DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) 2004-12-16 US disclosed
US-6815546-B2 ANTICANCER AGENTS SOCIETE DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2004-11-09 US disclosed
US-6797715-B1 Analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2004-09-28 US disclosed
US-6762301-B2 Analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them SOCIETE DE CONSEILS DE RECHERCHES ET APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2004-07-13 US disclosed
US-20030004150-A1 New analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them IPSEN PHARMA S.A.S. (FR) 2003-01-02 US disclosed
US-20020160994-A1 New analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) 2002-10-31 US disclosed
US-6339091-B1 USEFUL IN THERAPY OF OF VIRAL INFECTIONS, PARASITIC DISEASES AND CANCER SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2002-01-15 US disclosed
US-6313135-B1 FOR THERAPY OF LEUKEMIA, COLON CANCER OR LUNG CANCER IN WARM-BLOODED ANIMALS SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2001-11-06 US disclosed
US-5981542-A TOPOISOMERASE INHIBITORS; ANTITUMORAL DRUGS SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 1999-11-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254163-A1 New analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them TOP2A, TOP1, MCL1 KDM4E 4381/4885SMN1; SMN2 4584/4885ALDH1A1 778/4885
US-20030004150-A1 New analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them TOP1, TOP2A, TYMP KDM4E 4443/4885SMN1; SMN2 4010/4885ALDH1A1 795/4885
US-20050038064-A1 Anticarcinogenic agents; breast, colon, lung, prostate, ovarian, and gastric cancers, leukemia, melanomas; (5R)-5-ethyl-9,10-difluoro-5-hydroxy-4,5,13,15-tetrahydro-1H,3H-oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione MCL1, BRCA1, API5 KDM4E 699/4885SMN1; SMN2 3977/4885ALDH1A1 284/4885
US-20020160994-A1 New analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them TOP2A, TOP1, TOP2B KDM4E 4167/4885SMN1; SMN2 4560/4885ALDH1A1 1530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.